Outcomes-based access for Biologics

The Bruckner group has published a new article on the issues of market access for biologics (see press release) in Nature Biotechnology's February edition. Personally I think it couldn't be more timely and it is also very well written. I especially like the clearcut analysis about the unavoidable adaptation needs in business strategy and organizational structure of pharmaceutical and biotech companies in order to prepare their organizations for the changing healthcare/payer environment. It sums it up just right - a great read!

If you would like to receive the article you can either email David Balekdjian, Partner at the the Bruckner group, or send a note to me and I will forward a copy.

No comments: